- Price
- $312.34
- Day
- +1.60%
- Mkt Cap
- $25.61B
- 52W Range
- $244.52 – $316.11
- Volume
- 578.1K
- Beta
- 0.86
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read full article
First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.
Read full article
Labcorp NYSE: LH reported second-quarter 2026 revenue growth, margin expansion and higher adjusted earnings, prompting the laboratory services company to raise the midpoint of its full-year revenue and adjusted EPS guidance.
Read full article
Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call Transcript
Read full article
Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.
Read full article
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
Labcorp Holdings (LH) came out with quarterly earnings of $4.99 per share, beating the Zacks Consensus Estimate of $4.79 per share. This compares to earnings of $4.35 per share a year ago.
Read full article
Laboratory operator Labcorp raised its annual profit forecast and posted better-than-expected second-quarter results on Thursday, as steady demand for diagnostic testing and growth in its drug-development services business boosted performance.
Read full article
Results from operations for second quarter 2026 versus second quarter 2025: Revenue: $3.73 billion vs. $3.53 billion, up 5.8% Diluted EPS: $3.64 vs.
Read full article
Besides Wall Street's top-and-bottom-line estimates for Labcorp (LH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Read full article
New offering analyzes 163 genes linked to more than 100 medically actionable conditions Includes genetic counseling support to help consumers understand results and take informed next steps Consumers can now access biomarker and hereditary genetic testing from a single source through Labcorp OnDemand BURLINGTON, N.C., July 27, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of Marker by Labcorp™ Genetic Health Panel, a new offering designed to help consumers better understand inherited risks associated with more than 100 medically actionable health conditions.
Read full article
Labcorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read full article